Introduction to AMCG‘s New Listing on KRX’s KONEX

AMCG, known for its advanced heart disease diagnostic solutions, recently marked its presence on the Korea Exchange’s KONEX market. This significant step brings promising advancements in cardiac care technology to the forefront.

Background: AMCG and Its Technological Edge

AMCG, established in 2021, specializes in cutting-edge cardiac diagnostic devices. It uses Superconducting Quantum Interference Device (SQUID) technology, licensed from the Korea Research Institute of Standards and Science, for magnetocardiograph (MCG) systems. Here are some crucial aspects of AMC’s journey:

• It specializes in heart disease diagnostic devices.
• It received licenses from both Korean and US FDA.
• It aims to commercialize advanced diagnostic solutions internationally.

Innovative Products by AMCG

MCG-S: Current Flagship Model

AMCG’s first commercially available product, the MCG-S, is already operational in leading hospitals. It provides a comprehensive evaluation of suspected coronary artery disease through post-market clinical trials. These trials aim to assess MCG scan accuracy.

• Installed in two major hospitals.
• Undergoing clinical trials for accuracy evaluation.
• Aims for new medical technology approval by 2025.

MCG-F: Upcoming Lightweight Model

AMCG is also advancing its product line with the developmental MCG-F, set to penetrate the rapidly growing health screening market by 2025. This new model emphasizes portability and efficiency.

• Introduces lightweight design.
• Scheduled for regulatory approval in 2025.
• Targets expanding health check-up markets.

Overcoming Traditional Limitations

Traditional heart disease diagnostics often involve extended procedures and exposure to radiation risks, such as:

1. Stress electrocardiograms
2. Heart ultrasounds
3. SPECT scans
4. Cardiac CTs

AMCG’s MCG scanners leverage SQUID technology to detect minute magnetic signals produced by heart muscles, offering a safer, rapid alternative.

AMCG’s Market Prospects and Financial Highlights

Despite a challenging venture funding environment, AMCG secured substantial investments and government grants to bolster its technological and business potential:

• Raised 10 billion KRW in venture capital.
• Secured 1.2 billion KRW from government projects.
• Aims to transition to the KOSDAQ market within two years.

AMCG aims to become a global leader in early heart disease diagnosis, leveraging its KONEX listing as a springboard for future growth.

The Path Forward for AMCG

AMCG continues to focus on innovative solutions and strategic growth, underscoring its initiatives:

• Enhancing cardiac care diagnostics globally.
• Expanding product lines to address broader health diagnostics markets.
• Seeking international regulatory and market approvals.

In conclusion, AMCG’s listing on KONEX not only positions it for growth in cardiac diagnostics but also represents a crucial step in advancing patient care across the globe. By staying informed about such developments, you gain insights into the evolving field of medical technology and investment opportunities.

Table of Contents

1. Introduction
   • Overview of AMCG’s KONEX Listing
2. Background: AMCG and Its Technological Edge
   • Company Establishment and Mission
   • Technological Innovations
3. Innovative Products by AMCG
   • MCG-S: Current Flagship Model
   • MCG-F: Upcoming Lightweight Model
4. Overcoming Traditional Limitations
   • Challenges in Traditional Diagnostics
   • Advantages of SQUID Technology
5. AMCG’s Market Prospects and Financial Highlights
   • Recent Funding Success
   • Growth Plans for KOSDAQ Transition
6. The Path Forward for AMCG
   • Strategic Growth Initiatives
7. Conclusion
   • Future Impact on Cardiac Care and Diagnostics